BAE-SYSTEMS
10.12.2020 15:02:11 CET | Business Wire | Press release
BAE Systems, a world leader in electric propulsion , has delivered the first plug-in capable electric hybrid propulsion systems to Alexander Dennis Limited who are supplying new buses to Ireland. The Series-ER (Electric Range) systems will power Ireland’s fleet of up to 600 Enviro400ER hybrid buses. BAE Systems has supplied systems for the first 100 buses and will supply an additional 180 systems for buses next year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005589/en/
The Series-ER system builds on the company’s more than 20 years of innovation and proven technology and powers more than 13,000 buses around the world. That technology is on buses in service throughout Europe, including cities such as Brighton, London, Namur, and Paris. The Irish buses are the first in the world to benefit from the company’s new plug-in technology.
This means that as well as using the efficient onboard generator to charge itself while the bus is on the move, the buses can now also plug into the grid for power, giving operators another way to recharge their buses.
The Series-ER system enables buses to run for up to five kilometers (three miles) at a time with the engine turned off. This capability provides towns and cities with a new opportunity to improve air quality. The buses will use up to 35 percent less fuel when compared to a conventional bus.
“Clean transportation technology in our cities is critical to reach a zero emission future,” said Ian Wilson, director of business development for Power & Propulsion Solutions at BAE Systems. “Our system will help Ireland take the next step towards full electrification and improve the air quality where people live, work and visit.”
“The Alexander Dennis Enviro400ER is ideally suited for flexible operating needs including zero-emission running at air pollution hotspots,” said Paul Davies president and managing director at ADL. “With the ability to externally charge the batteries, the use of on-board power generation can be further reduced. This new generation of double deck buses for Ireland once again demonstrates that with ADL’s focus on innovation, we are building the buses our cities need to solve their transport challenges.”
The bus propulsion system includes a highly efficient electric motor and generator, an enhanced battery, and smart electronic controls to create a clean form of electric drive propulsion for the buses. It allows operators to take advantage of green grid power, and sets them up for full electric operation in the future. Operators can now use the grid for power – much like an all-electric bus – and add more battery capacity to increase their engine off time. In many instances this will mean an entire route can operate on grid power when the necessary charging infrastructure is in place.
BAE Systems develops and services its technology at its facilities in Endicott, New York, and Rochester, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
